Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zymeworks ( (ZYME) ) just unveiled an update.
Zymeworks Inc. has appointed Dr. Adam Schayowitz as Acting Chief Development Officer to further advance its portfolio of therapeutic candidates and strengthen strategic partnerships. Dr. Schayowitz, with extensive experience in oncology drug development, will work closely with Zymeworks’ R&D and Business Development teams to accelerate the company’s efforts in bringing innovative therapies to market, enhancing its industry positioning and potential impact on patients worldwide.
The most recent analyst rating on (ZYME) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
Zymeworks’ overall score is driven by strong earnings call insights, including revenue growth and regulatory successes. However, financial performance and valuation concerns, particularly profitability and cash flow issues, weigh down the score. Technical analysis provides a positive outlook, but the negative P/E ratio and lack of dividends are significant detractors.
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a global clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel, multifunctional biotherapeutics. The company aims to address difficult-to-treat conditions such as cancer, inflammation, and autoimmune diseases. Zymeworks utilizes complementary therapeutic platforms and a fully integrated drug development engine to engineer and develop differentiated antibody-based therapeutic candidates. One of its key products, zanidatamab, a HER2-targeted bispecific antibody, has received various regulatory approvals and is being evaluated in global clinical trials.
Average Trading Volume: 516,920
Technical Sentiment Signal: Buy
Current Market Cap: $1.25B
Learn more about ZYME stock on TipRanks’ Stock Analysis page.